Jesús Fuentes-Antrás

6PUBLICATIONS
40CO-AUTHORS
Molecular targetsPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Nov 03, 2025
Dabogratinib (TYRA-300), an FGFR3 Isoform-Selective Inhibitor: Preclinical and Initial Clinical Evidence of Antitumor Activity.

Jacqueline H Starrett, Eric L Allen, Melissa Neal

|Oct 14, 2025
Dabogratinib (TYRA-300), an FGFR3 Isoform-Selective Inhibitor: Preclinical and Initial Clinical Evidence of Antitumor Activity.

Jacqueline H Starrett, Eric L Allen, Melissa Neal

|Jan 09, 2025
Ultrasensitive Detection and Monitoring of Circulating Tumor DNA Using Structural Variants in Early-Stage Breast Cancer.

Mitchell J Elliott, Karen Howarth, Sasha Main

|Jan 24, 2024
Seize the engine: Emerging cell cycle targets in breast cancer.

Jesús Fuentes-Antrás, Philippe L Bedard, David W Cescon

|Dec 03, 2020
A snapshot of COVID-19 infection in patients with solid tumors.

Jesús Fuentes-Antrás, Aránzazu Manzano, Gloria Marquina

|Jul 12, 2017
Multiple modes of Lrp4 function in modulation of Wnt/β-catenin signaling during tooth development.

Youngwook Ahn, Carrie Sims, Megan J Murray

Pageof 1